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I. Experimental Procedures 
 
General Unless otherwise noted, all chemicals and reagents were obtained from commercial 
suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used without further purification. Silica gel 
chromatography was carried out using AMD Silica Gel 60, 230-400 mesh. Synthetic reactions 
were monitored using thin layer chromatography (Merck 60 gel plates) using a UV-lamp for 
visualization. 1H and 13C NMR spectra were recorded on a Varian Inova 300 MHz or 500 MHz, 
or Bruker Prodigy 400 MHz instrument, in CDCl3 and are internally referenced to the residual 
solvent peak. Data for 1H NMR are reported as follows: chemical shift (δ ppm), multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, dd = doublet of doublets, dt 
= doublet of triplets, ddd = doublet of doublet of doublets), coupling constant (Hz), integration. 
High-resolution mass spectra were obtained at the California Institute of Technology Mass 
Spectrometry Facility.  
 
Chromatography. Analytical high-performance liquid chromatography (HPLC) was carried out 
using an Agilent 1200 series instrument and an Agilent Eclipse XDB-C18 column 
(4.6 x 150 mm, 5 μm) with water and acetonitrile as the mobile phases. Exemplary HPLC runs for 
N-vinylphthalimide cyclopropanation are shown in Figure S7. For quantitative HPLC analysis of 
N-vinylphthalimide cyclopropanation reaction products, calibration curves using ethyl benzoate as 
internal standard were generated (Figure S8). The identity of the reaction products was confirmed 
by HPLC co-injections of reaction mixtures with chemically synthesized authentic products, and 
by NMR analysis of products isolated from reactions performed on preparative scale. 
Cyclopropanation product enantiomers were separated using chiral SFC with isopropanol and 
liquid CO2 as the mobile phase, or chiral HPLC with isopropanol and hexane as the mobile phase. 
Product enantiomers were separated using Chiralpak IA, IC, or OJ-H columns (4.6 x 250 mm, 5 
μm) from Chiral Technologies Inc. 
 
Cloning and site-saturation mutagenesis. pET22b(+) with the pelB leader sequence removed 
was used as a cloning and expression vector for all constructs described in this study. Site-
saturation libraries were generated employing the 22c-trick method1. The resulting PCR products 
were gel purified, digested with DpnI, repaired using the method of Gibson2, and used to directly 
transform E. coli strain BL21(DE3). 
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Determination of P411 concentration. The concentration of P411 enzymes in whole cell 
experiments was determined from ferrous carbon monoxide binding difference spectra using the 
previously reported extinction coefficient for serine-ligated enzymes (ε = 103,000 M–1 cm–1)3. The 
concentration of purified P411 enzymes was determined by quantifying the amount of free hemin 
using the pyridine/hemochrome assay using the corresponding extinction coefficient (ε = 191,500 
M–1 cm–1)4. 
 
Expression and small-scale N-vinylphthalimide cyclopropanation bioconversions using 
whole cells. E. coli BL21(DE3) cells transformed with plasmid encoding P411 variants were 
grown overnight in 3 mL Luria-Bertani medium with 0.1 mg/mL
 
ampicillin (LBamp) at 30 ºC and 
250 rpm. Precultures were centrifuged (3000 g, 3 minutes), the supernatant was discarded, and cell 
pellets were resuspended in 3 mL fresh LBamp and used to inoculate 47 mL of Hyperbroth medium 
(prepared from AthenaES© powder, 0.1 mg/mL
 
ampicillin) in a 125 mL Erlenmeyer flask. 
Cultures were incubated at 37 ºC, 230 rpm for 2 h, typically reaching an OD600 = 1.5. Cultures 
were then cooled on ice (20 min) and induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and 1.0 mM 5-aminolevulinic acid (ALA) (final concentrations). Expression was 
conducted at 22 ºC, 130 rpm, for 16-18 h. Cultures were then centrifuged (3000 g, 5 min, 4 ºC) 
and the pellets were resuspended to OD600= 30 in M9-N minimal medium (47.7 mM Na2HPO4, 
22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2, pH 6.8). To determine 
P411 expression levels, aliquots of the cell suspension (4 mL) were lysed by sonication (Qsonica 
Q500 sonicator), and the lysate was cleared by centrifugation (13,000 g, 10 min, 4 ºC) and 
subjected to the carbon monoxide binding assay specified above. 
 
Small-scale cyclopropanation reactions were set up in 2 mL crimp vials at 500 μL reaction volume. 
P411-expressing cells at OD600 = 30 in M9-N were degassed by sparging with argon in sealed 6 
mL crimp vials for at least 30 minutes. Separately, a glucose solution (500 mM in M9-N) was 
degassed by sparging with argon for at least ten minutes. Following argon sparging, cells, glucose 
solution, and substrate solutions were transferred into an anaerobic chamber. The cells (440 or 
465 μL) were added to 2 mL crimp vials, followed by glucose solution (10 μL), olefin (12.5 or 
25 μL of a DMSO stock), and EDA (12.5 or 25 μL of an EtOH stock). Final concentrations were 
typically 5 to 30 mM olefin, 10 to 60 mM EDA, 10 mM glucose, and 5 or 10% cosolvent. The 
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vials were sealed, removed from the anaerobic chamber, and shaken at room temperature, 500 rpm 
for 16–20 h. The reactions were quenched by adding acetonitrile (1.5 mL) supplemented with 
internal standard (ethyl benzoate, to 0.5 mM final concentration). This mixture was transferred to 
a 2 mL microcentrifuge tube and centrifuged at 13,000 g for 10 minutes. The cleared supernatant 
was transferred to a vial and analyzed by HPLC. 
 
Site-saturation library screening in 96-well plate format. Single colonies of
 
E. coli cells 
transformed with site-saturation libraries were picked with sterile toothpicks and cultured in 96-
well deep-well plates in LBamp (300 μL/well) at 37 ºC, 250 rpm, overnight. In a fresh 96-well deep-
well plate, hyperbroth medium (950 μL/well, 0.1 mg/mL
 
ampicillin) was inoculated with the 
precultures (50 μL/well) and incubated at 37 ºC, 250 rpm, for 2.5 h. The plates were cooled on ice 
for 20 minutes and then induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). 
Expression was conducted at 20 ºC, 200 rpm for 20 h. The cells were pelleted (3,000 g, 5 min), 
the supernatant discarded, and the 96-well plates were transferred to an anaerobic chamber. In the 
anaerobic chamber, cell pellets were resuspended in argon-sparged reaction buffer (20 mM glucose 
in M9-N, 470 μL/well), and stocks of olefin (15 μL/well, in DMSO) and EDA (15 μL/well, in 
EtOH) were added. Substrate concentration varied in the course of directed evolution between 10 
and 30 mM for both EDA and N-vinylphthalimide. In later screening rounds, cells were 
resuspended in 440 μL M9-N/glucose buffer followed by addition of 30 μL of each substrate stock, 
in order to achieve higher co-solvent concentrations and thus aid with N-vinylphthalimide 
solubility at higher substrate concentrations. The plates were sealed with aluminum foil, removed 
from the anaerobic chamber, and shaken at 50 rpm. After overnight incubation, the seal was 
removed and acetonitrile (500 μL/well) supplemented with internal standard (ethyl benzoate, to 
0.5 mM final concentration) was added. The plates were resealed, briefly mixed by vortexing, and 
incubated for 30 min to 1 h at room temperature. The plates were then centrifuged (5,000 g, 10 
min), and the cleared supernatant was filtered through an AcroPrep 96-well filter plate (0.2 μm 
cutoff) into a shallow-well plate for HPLC analysis. 
 
Protein purification. E. coli BL21(DE3) cells freshly transformed with plasmid encoding P411 
variants were grown overnight in 25 mL LBamp (30 ºC, 250 rpm). Hyperbroth medium (500 mL, 
0.1 mg/mL
 
ampicillin) in a 2.8 L flask was inoculated with 20 mL of the preculture and incubated 
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at 37 ºC, 230 rpm for 2 h (to OD600 ca. 1.5). Cultures were then cooled in an ice-water bath for 20 
min and induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was 
conducted at 22 ºC, 140 rpm, for 16-20 h. Cultures were then centrifuged (5,000 g, 10 min, 4 ºC) 
and the cell pellets were frozen at –20 ºC. For protein purification, frozen cells from two such 
cultures were resuspended in buffer A (25 mM tris, 20 mM imidazole, 100 mM NaCl, pH 7.5, 4 
mL/g of cell wet weight), loaded with hemin (1 mg/gram wet cell weight) and lysed by sonication. 
To pellet insoluble material, lysates were centrifuged (20,000 g, 20 min, 4 ºC). P411 proteins were 
purified from the lysate using a nickel NTA column (1 mL HisTrap HP, GE Healthcare, 
Piscataway, NJ) using an AKTAxpress purifier FPLC system (GE healthcare). P411 enzymes were 
eluted on a linear gradient from 100% buffer A to 100% buffer B (25 mM tris, 300 mM imidazole, 
100 mM NaCl, pH 7.5) over 10 column volumes. Fractions containing eluted protein were pooled 
and subjected to three rounds of buffer exchange to storage buffer (25 mM Tris-HCl, 25 mM NaCl, 
pH 7.5) using centrifugal spin filters (10 kDa molecular weight cut-off, Amicon Ultra, Merck 
Millipore). Subsequently, the concentrated protein was aliquoted, flash-frozen on powdered dry 
ice, and stored at –80 ºC. Protein concentrations were determined via the pyridine/hemochrome 
assay specified above.  
 
Cyclopropanation reactions using purified protein. Portions of M9-N buffer (290 μL) and 
NADPH (40 μL, 50 mM in M9-N), or multiples thereof, were combined in a 6 mL crimp vial and 
degassed by sparging with argon for at least 30 minutes. Purified protein solutions were adjusted 
to 25 μM in M9-N. After degassing was complete, the M9-N/NADPH solution and purified protein 
stocks were brought into the anaerobic chamber. Reactions were set up on a 400 μL scale in 2 mL 
crimp vials: first, 330 μL of the M9-N/NADPH solution were added per vial, followed by 40 μL 
of purified protein solution. Next, 20 μL of N-vinylphthalimide stock solution (100 mM in DMSO) 
were added, followed by 10 μL of EDA stock solution (200 mM in EtOH). Final concentrations 
were typically 5 mM N-vinylphthalimide, 5 mM EDA, 5 mM NADPH, and 2.5 μM P411, with 
7.5% co-solvent. The vials were sealed, removed from the anaerobic chamber, and shaken at room 
temperature, 40 rpm for 1 to 6 h. The reactions were quenched by adding acetonitrile (400 μL) 
supplemented with internal standard (ethyl benzoate, to 0.5 mM final concentration). This mixture 
was transferred to a microcentrifuge tube and centrifuged at 14,000 rpm for 10 minutes. The 
supernatant was transferred to a vial and analyzed by HPLC.  
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Determination of initial rates. (i) With purified protein: Reactions were set up as described above 
(Cyclopropanation reactions using purified protein). Reactions were quenched in 1-minute 
intervals (starting 2 min after the start of the reaction) by addition of 400 μL acetonitrile containing 
internal standard, followed by vigorous mixing. The samples were then worked up and analyzed 
as described above. (ii) With whole cells: Reactions were set up as described above (Expression 
and small-scale N-vinylphthalimide cyclopropanation bioconversions using whole cells). 
Reactions were quenched in 1-minute intervals (starting 2 min after the start of the reaction) by 
addition of 500 μL acetonitrile, followed by vigorous mixing. The vials were removed from the 
anaerobic chamber and 1 mL of acetonitrile supplemented with internal standard (ethyl benzoate, 
to 0.5 mM final concentration) was added. Further sample work-up and HPLC analysis was 
performed as described above. 
 
Preparative scale reactions. E. coli BL21(DE3) cells freshly transformed with plasmid encoding 
P411 variants were grown overnight in 25 mL LBamp (30 ºC, 250 rpm). Hyperbroth medium (500 
mL, 0.1 mg/mL
 
ampicillin) in a 2.8 L flask was inoculated with 20 mL of the preculture and 
incubated at 37 ºC, 230 rpm for 2 h (to OD600 ca. 1.5). Cultures were then cooled in an ice-water 
bath for 20 min and induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). 
Expression was conducted at 22 ºC, 140 rpm, for 16-20 h. Cultures were then centrifuged (5,000 g, 
5 min, 4 ºC) and the cell pellets were resuspended to OD600 = 50 in M9-N buffer supplemented 
with 20 mM glucose (typically yielding ca. 110 mL of cell suspension). Aliquots of the cell 
suspension (4 mL) were used to determine the P411 expression level after cell lysis by sonication. 
Aliquots of the cell suspension (23 mL) were then transferred to 50 mL Erlenmeyer flasks and 
degassed by sparging with argon for at least 30 minutes. The reaction flasks were then transferred 
into an anaerobic chamber and olefin stock solution (1 mL, in DMSO) and EDA (1 mL, in EtOH) 
were added. Final concentrations were typically 5 to 20 mM olefin and 10 to 40 mM EDA, with 
8% co-solvent. The flasks were sealed with parafilm, removed from the anaerobic chamber, and 
shaken at room temperature, 100 rpm for 18 h. The reactions were quenched by adding acetonitrile 
(25 mL) and then centrifuged (4,000 g, 10 min). The supernatant was concentrated in vacuo to 
remove acetonitrile and extracted with EtOAc (3 x 25 mL). The organic layers were washed with 
brine (20 mL), dried over MgSO4, filtered, concentrated, and purified by silica gel 
chromatography. 
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Assignment of absolute configuration. To assign the absolute configuration of the trans-
configured N-vinylphthalimide cyclopropanation product (ethyl trans-2-(1,3-dioxoisoindolin-2-
yl)cyclopropane-1-carboxylate, 3b), purified product from preparative-scale enzymatic reactions 
with P411-VACtrans was subjected to crystallization and X-ray structure determination (Table S1). 
Low-temperature diffraction data (-and -scans) were collected on a Bruker AXS D8 VENTURE 
KAPPA diffractometer coupled to a PHOTON 100 CMOS detector with Cu K radiation ( = 
1.54178 Å) from an IμS micro-source. The structure was solved by direct methods using SHELXS 
and refined against F2 on all data by full-matrix least squares with SHELXL-20165 using 
established refinement techniques. All non-hydrogen atoms were refined anisotropically. All 
hydrogen atoms were included into the model at geometrically calculated positions and refined 
using a riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups). Ethyl trans-2-
(1,3-dioxoisoindolin-2-yl)cyclopropane-1-carboxylate 3b crystallizes in the orthorhombic space 
group P212121 with one molecule in the asymmetric unit. The absolute configuration was assigned 
as trans-(1S, 2S) (Figure S1). The absolute configurations of other cyclopropanes formed by P411-
VACtrans were assigned by analogy. Crystallographic coordinates and structure factors for ethyl 
trans-2-(1,3-dioxoisoindolin-2-yl)cyclopropane-1-carboxylate 3b have been deposited with the 
Cambridge Crystallographic Data Centre (https:// www.ccdc.cam.ac.uk/) under reference number 
1815565. 
 
Attempts to crystallize the cis-configured N-vinylphthalimide cyclopropanation product were 
unsuccessful; furthermore, attempts to crystallize alternative cis-configured products derived from 
P411-VACcis (Table 1) were unsuccessful as well. We therefore determined the selectivity of 
P411-VACcis in the cyclopropanation reaction of styrene with EDA (Figure S2), as previously 
described6. To this end, whole-cell reactions with E. coli cells expressing P411-VACcis at 
OD600=30 were performed with 10 mM styrene and 10 mM EDA, following the protocol described 
above (Expression and small-scale N-vinylphthalimide cyclopropanation bioconversions using 
whole cells). Reactions were extracted with cyclohexane and analyzed by GC using a Cyclosil-B 
column (30m x 0.32 mm x 0.25 µm), oven temperature = 100 °C for 5 min, 1 °C per min to 135°C, 
135 °C for 10 min, 10 °C per min to 200 °C, 200 °C for 5 min6. Using a racemic product standard 
for comparison and a previously developed assay6, the major styrene cyclopropanation product 
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isomer derived with P411-VACcis was thereby assigned as (1S, 2R), and we assigned the absolute 
configuration of other cyclopropanes formed by P411-VACcis (or its single point mutation 
derivatives) by analogy. Of note, we also included P411-VACtrans in this experiment; the major 
styrene cyclopropanation product isomer obtained with this variant is the (1S, 2S) isomer, in 
agreement with the absolute configuration obtained by crystal structure determination (Figures S1, 
S2). 
 
Figure S1: Crystal structure of ethyl trans-2-(1,3-dioxoisoindolin-2-yl)cyclopropane-1-
carboxylate, 3b. The absolute configuration of 3b was assigned as (1S, 2S). 
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Table S1. Crystal data and structure refinement for ethyl (1S, 2S)-2-(1,3-dioxoisoindolin-2-yl) 
cyclopropane-1-carboxylate (3b). 
 
Empirical formula  C14H13NO4 
Formula weight  259.25 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.6275(5) Å, α = 90° 
 b = 8.0167(7) Å, β = 90° 
 c = 22.6419(19) Å, γ = 90° 
Volume 1202.98(17) Å3 
Z 4 
Density (calculated) 1.431 Mg/m3 
Absorption coefficient 0.883 mm-1 
F(000) 544 
Crystal size 0.350 x 0.300 x 0.250 mm3 
Theta range for data collection 3.905 to 74.466° 
Index ranges -8<=h<=8, -10<=k<=10, -28<=l<=25 
Reflections collected 13445 
Independent reflections 2442 [R(int) = 0.0319] 
Completeness to theta = 67.679° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.6780 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2442 / 0 / 173 
Goodness-of-fit on F2 1.154 
Final R indices [I>2sigma(I)] R1 = 0.0334, wR2 = 0.0889 
R indices (all data) R1 = 0.0336, wR2 = 0.0892 
Absolute structure parameter 0.07(5) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.218 and -0.329 e.Å-3 
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Figure S2: Assigning absolute configuration of styrene cyclopropanation products obtained 
with P411-VACcis and P411-VACtrans. We tested P411-VACcis and P411-VACtrans for the 
cyclopropanation of styrene with EDA (see section Assignment of N-vinylphthalimide 
cyclopropanation product absolute configuration above for experimental details). For P411-
VACcis, this delivered the (1S, 2R) isomer as major product, and the absolute configuration of other 
P411-VACcis cyclopropanation products was assigned by analogy. The major styrene 
cyclopropanation product isomer obtained with P411-VACtrans was assigned as (1S, 2S), in 
agreement with the absolute configuration of the N-vinylphthalimide cyclopropanation product 
obtained with that variant as determined by crystallography (vide supra).  
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II. Supplementary Tables 
 
Table S2. Hemoprotein variant screening for N-vinylphthalimide cyclopropanation. 
 
 
 
Hemoprotein 
varianta 
Description, mutations, references Yield [%] dr (cis:trans) 
Heminb Free hemin in buffer, no protein 1.5 28:72 
E. coli BL21(DE3) No protein overexpression N.D. - 
P450BM3 Wild-type P450BM3 0.2 37:63 
P450BM3 T268A P450BM3 with mutation T268A
6 0.2 39:61 
P450BM3 T268A 
C400S 
P450BM3 with mutations T268A and C400S
7 0.5 31:69 
P450BM3 T268A 
C400H 
P450BM3 with mutations T268A and C400H  0.5 35:65 
P450BM3-CIS 
P450BM3 with mutations V78A F87V P142S 
T175I A184V S226R H236Q E252G 
T268A A290V L353V I366V E442K6 
0.3 56:54 
P411BM3-CIS
7 P450BM3-CIS with C400S mutation 2.0 88:12 
P450BM3-CIS 
C400H 
P450BM3-CIS with C400H mutation 1.6 74:26 
H2-5-F10 
P450BM3 with mutations L75A V78A F87V 
P142S T175I A184V S226R H236Q E252G 
I263A T268A A290V L535V I366V 
L437A E442K6 
0.2 45:55 
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H2-5-F10 C400S H2-5-F10 with mutation C400S 1.1 56:54 
H2-5-F10 C400H H2-5-F10 with mutation C400H 0.5 35:65 
HStar H92N 
H100N 
P450BM3 with mutations V78M H92N 
H100N L181V T268A C400H L437W8, 9 
0.5 27:73 
P450-Cam P450cam from Pseudomonas putida10 0.5 38:62 
Cyp119 Cyp119 from Sulfolobus acidocaldarius11 0.9 44:56 
Cyt c Rma TDE 
Cytochrome c from Rhodothermus marinus 
evolved for carbene Si–H insertion12 
1.2 28:72 
Ape protoglobin Protoglobin from Aeropyrum pernix13 0.6 52:48 
 
a Reactions were performed in 96-well plates with whole E. coli cells expressing the respective 
hemoprotein variants, at 20 mM substrate loading. Results are the average of duplicate reactions. 
N.D. = not detected. b Reaction with hemin: in the anaerobic chamber, 40 μL of hemin solution 
(1 mM in DMSO) were added to 310 μL of argon-sparged M9-N buffer, followed by 10 μL of 
sodium dithionite as reductant (400 mM in M9-N buffer), N-vinylphthalimide (20 μL, 400 mM in 
DMSO) and EDA (20 μL, 400 mM in DMSO). Final concentrations were 100 μM hemin, 10 mM 
sodium dithionite, 20 mM N-vinylphthalimide and 20 mM EDA with 20% co-solvent (DMSO). 
The observed yield corresponds to 3 TTN. Note that P450 variants in 96-well plates typically 
express at ~0.5 μM, i.e. 200-fold lower than the hemin concentration tested here.  
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Table S3a. Summary of directed evolution for cis-selective N-vinylphthalimide cyclopropanation. 
Round Parent variant Site-saturation 
libraries evaluateda 
Screening 
substrates 
Mutations 
identified 
1 P411BM3-CIS 
V87X, L181X, I263X, 
T268X, L437X, T438X 
N-vinylphthalimide 
EDA 
V87T, 
I263A/F/G, 
L437F/Y, 
T438C/Q 
2 P411BM3-CIS 
Recombination library 
of mutationsb: V87T, 
I263A/F/G, L437F/Y, 
T438C/Q 
N-vinylphthalimide 
EDA 
L437F T438Q 
3 
P411BM3-CIS 
L437F T438Q  
A328X, Q387X, I263X, 
A264X, L75X 
N-vinylphthalimide 
EDA 
L75Y 
4 
P411BM3-CIS 
L437F T438Q 
L75Y 
V87X, L181X 
N-vinylphthalimide 
EDA L181I 
Final variant: P411-VACcis = P411BM3-CIS L75Y L181I L437F T438Q 
 
a Some residues were saturated twice, in different parent variants. b The corresponding wild-type 
residues at each position were included in the recombination library. 
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Table S3b. Summary of directed evolution for trans-selective N-vinylphthalimide 
cyclopropanation. 
Round Parent variant Site-saturation 
libraries evaluateda 
Screening 
substrates 
Mutations 
identified 
1 P411BM3-CIS 
V87X, L181X, I263X, 
T268X, L437X, T438X 
N-vinylphthalimide 
EDA 
V87T, 
I263A/F/G, 
L437F/Y, 
T438C/Q 
2 P411BM3-CIS 
Recombination library 
of mutationsb: V87T, 
I263A/F/G, L437F/Y, 
T438C/Q 
N-vinylphthalimide 
EDA 
I263G L437F 
3 
P411BM3-CIS 
I263G L437F 
A328X, T438X, L75X, 
V87X 
N-vinylphthalimide 
EDA 
V87L 
4 
P411BM3-CIS 
I263G L437F 
V87L 
L181X 
N-vinylphthalimide 
EDA L181R 
Final variant: P411-VACtrans = P411BM3-CIS V87L L181R I263G L437F 
 
a Some residues were saturated twice, in different parent variants. b The corresponding wild-type 
residues at each position were included in the recombination library.   
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Table S4. N-vinylphthalimide cyclopropanation reactions performed with purified P411 variants.a 
 
 
Catalyst Yield [%] TTN dr [cis:trans] ee [%] 
P411BM3-CIS 6.1 120 64:36 -9 
P411-VACcis 31 620 91:9 93 
P411-VACtrans 26 510 8:92 84 
 
a Reactions were performed with 2.5 μM P411, 5 mM NADPH, 5 mM N-vinylphthalimide, and 
5 mM EDA; results are the average of duplicate reactions. 
 
 
Table S5. Library of P411-VACcis variants with single active site mutations at residues V87, 
I263, E267 and A328. 
 
Position Variantsa 
V87 F, C, T, I 
I263 A, T, V 
E267 V, N, Q 
A328 N, T, S, Q 
 
a These variants were identified in the course of directed evolution projects aimed at improving 
P411-VACcis for unactivated alkene cyclopropanation reactions
13. 
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III. Supplementary Figures 
 
Figure S3: Position of active site mutations in P411-VACtrans and P411-VACcis variants. 
Structures are based on the parent enzyme P411BM3-CIS (pdb: 4h23)
7 and depict the active site 
with the heme cofactor. The sidechains of residues mutated in P411-VACtrans and P411-VACcis 
are shown as colored sticks. All residues targeted for mutagenesis were chosen due to their 
proximity to the heme cofactor and because mutations at these positions were known to affect 
activity or selectivity of cytochrome P450-catalyzed cyclopropanation reactions.6,7,9,13 (A) Position 
of altered residues (yellow) in variant P411-VACtrans (P411BM3-CIS I263G L437F V87L L181R). 
(B) Position of altered residues (red) in variant P411-VACcis (P411BM3-CIS L437F T438Q L75Y 
L181I). (C) Positions of additional single-residue mutations (blue) in P411-VACcis to enhance 
diastereo- and enantioselectivities across multiple substrates (see Table 1, Figure S6). Ongoing 
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structure determination efforts may provide further insight into the molecular basis of the catalytic 
activity and diastereoselectivity of P411-VACtrans and P411-VACcis. 
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Figure S4: Maximizing TTN for P411-VACcis. To test for maximal TTN of the cis-selective 
variant P411-VACcis two different reaction conditions were investigated. First, N-vinylphthalimide 
substrate loading was increased to 45 mM (compared to 30 mM as shown in Figure 1A) with 60 
mM EDA, using whole cell catalysts at OD600=30. Under these conditions, 74% yield and 39,000 
TTN were observed (left bars). Secondly, catalyst loading was reduced by using cells at OD600=10, 
with 20 mM N-vinylphthalimide and 20 mM EDA. Under these conditions, 57% yield and 41,000 
TTN were observed (right bars). In both cases, dr and ee were essentially unchanged. Results are 
the average of duplicate reactions.  
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Figure S5: Determination of initial rates. (A) Apparent initial rates estimated with purified P411 
variants. Reactions contained 2.5 µM P411, 5 mM NADPH, 5 mM N-vinylphthalimide and 5 mM 
EDA in M9-N buffer. (B) Apparent initial rates estimated with whole cells expressing the P411 
variants. Reactions contained cells at OD600=30 in M9-N buffer and 30 or 5 mM N-
vinylphthalimide with 60 or 10 mM EDA for the cis- or trans-selective variants P411-VACcis or 
P411-VACtrans, respectively. Reactions were performed under anaerobic conditions. Results are 
the average of duplicate reactions at each time point.   
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Figure S6: Improving diastereo- and enantioselectivities of P411-VACcis across diverse 
substrates by screening a small, focused library. Shown are dr and ee obtained with P411-
VACcis and variants thereof containing single additional active site mutations identified in the 
screen of the small, focused library shown in Table S5. (A) cis-selective N-vinylcaprolactam 
cyclopropanation; (B) cis-selective N-vinylpyrrolidone cyclopropanation; (C) cis-selective N-
methyl-N-vinylacetamide cyclopropanation; (D) cis-selective phenyl vinyl ether 
cyclopropanation; (E) trans-selective phenyl vinyl ether cyclopropanation; (F) cis-selective phenyl 
vinyl sulfide cyclopropanation; (G) trans-selective phenyl vinyl sulfide cyclopropanation; (H) cis-
selective N-vinylcarbazole cyclopropanation. For all substrates tested, variants showing enhanced 
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diastereo- or enantioselectivities compared to P411-VACcis could be identified. Of note, this 
screening approach also resulted in the identification of two P411-VACcis variants with trans 
diastereoselectivity for substrates phenyl vinyl ether (E) and phenyl vinyl sulfide (G). 
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Figure S7: HPLC analysis parameters and example chromatograms. (A) Chromatography 
method employed on an Agilent Eclipse XDB-C18 column to analyze N-vinylphthalimide 
cyclopropanation reactions. Retention times of reaction components are indicated. (B) Exemplary 
HPLC run with P411 variant P411-VACcis. Note that this sample was taken before the reaction 
was complete, hence large amounts of starting materials EDA and N-vinylphthalimide are present. 
(C) Exemplary HPLC run with P411 variant P411-VACtrans.  
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Figure S8: HPLC calibration curves. HPLC calibration curves employing ethyl benzoate as 
internal standard for (A) the cis and (B) the trans N-vinylphthalimide cyclopropanation products.  
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IV. Characterization of reaction products 
Reactions were performed according to the general protocol described above (Preparative scale 
reactions). Spectral data of known compounds are in agreement with reported values.14-19 
 
 
 
 
 
3a: Ethyl (1S, 2R)-2-(1,3-dioxoisoindolin-2-yl)cyclopropane-1-carboxylate. The reaction was 
performed on 4.0 mmol scale with whole-cell catalysts at OD600=50 in 90 mL M9-N buffer 
expressing P411-VACcis at 1.2 μM, with 40 mM N-vinylphthalimide (added as 5 mL of a 800 mM 
solution in DMSO) and 60 mM EDA (added as 5 mL of a 1.2 M solution in EtOH). The product 
was purified by silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a clear oil 
(996 mg, 96% yield, 32,000 TTN, 97:3 dr, 97% ee). 1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 
5.4, 3.1 Hz, 2H), 7.69 (dd, J = 5.4, 3.1 Hz, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.01 (ddd, J = 7.8, 7.1, 
5.8 Hz, 1H), 2.18 (dt, J = 8.8, 6.9 Hz, 1H), 1.94 (q, J = 6.3 Hz, 1H), 1.63 (ddd, J = 8.8, 7.7, 6.3 
Hz, 1H), 1.16 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.60, 168.69, 134.19, 131.75, 
123.43, 61.08, 27.62, 19.04, 14.16, 13.07. HRMS (FAB+) exact mass calculated for C14H14NO4
+ 
requires m/z 260.0923, found 260.0915. 
 
 
 
 
 
3b: Ethyl (1S, 2S)-2-(1,3-dioxoisoindolin-2-yl)cyclopropane-1-carboxylate. The reaction was 
performed on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer 
expressing P411-VACtrans at 7.2 μM, with 5 mM N-vinylphthalimide (added as 1 mL of a 125 mM 
solution in DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product 
was purified by silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a white solid 
(28.5 mg, 88% yield, 610 TTN, 3:97 dr, 92% ee). 1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 5.5, 
3.0 Hz, 2H), 7.72 (dd, J = 5.5, 3.0 Hz, 2H), 4.20 (q, J = 7.2 Hz, 2H), 3.30 (ddd, J = 8.2, 5.2, 3.1 
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Hz, 1H), 2.21 (ddd, J = 9.3, 6.2, 3.2 Hz, 1H), 1.75 (ddd, J = 9.3, 5.7, 5.2 Hz, 1H), 1.63 (ddd, J = 
8.1, 6.2, 5.8 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.26, 168.16, 
134.37, 131.65, 123.48, 61.23, 29.61, 20.09, 14.35, 13.69. HRMS (FAB+) exact mass calculated 
for C14H14NO4
+ requires m/z 260.0923, found 260.0928. 
 
Determination of N-vinylphthalimide cyclopropanation enantioselectivity. Reaction mixtures 
were extracted with cyclohexane, or purified compounds were dissolved in 20% isopropanol in 
hexanes, and samples were analyzed by chiral SFC using a Chiralpak AD-H column (10% 
isopropanol, isocratic).  
 
Racemic cis isomer, chemically prepared: 
 
Enzymatic reaction with P411-VACcis (97% ee cis (1S, 2R) isomer): 
 
Racemic trans isomer, chemically prepared: 
 
Enzymatic reaction, with P411-VACtrans (92% ee trans (1S, 2S) isomer): 
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4a: Ethyl (1S, 2R)-2-(2-oxoazepan-1-yl)cyclopropane-1-carboxylate. The reaction was 
performed on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer 
expressing P411-VACcis V87T at 1.5 μM, with 5 mM N-vinylcaprolactam (added as 1 mL of a 125 
mM solution in DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 100% EtOAc/hexanes) and isolated as a 
clear oil (21.8 mg, 78% yield, 2600 TTN, 95:5 dr, 88% ee). 1H NMR (400 MHz, CDCl3) δ 4.09 
(q, J = 7.1 Hz, 2H), 3.48 (ddd, J = 15.2, 9.2, 1.6 Hz, 1H), 3.39 (ddd, J = 15.2, 7.6, 1.9 Hz, 1H), 
3.07 (td, J = 7.5, 6.1 Hz, 1H), 2.45 (dd, J = 6.6, 4.2 Hz, 2H), 2.13 (ddd, J = 8.4, 7.4, 6.3 Hz, 1H), 
1.91 – 1.77 (m, 2H), 1.69 – 1.56 (m, 4H), 1.37 (q, J = 6.2 Hz, 1H), 1.28 – 1.18 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ 177.58, 170.59, 60.60, 51.13, 38.75, 37.58, 30.08, 27.84, 23.01, 22.98, 14.14, 
13.44. HRMS (ESI) exact mass calculated for C12H19NO3
+ requires m/z 226.1443, found 
226.1413. 
 
 
 
 
 
4b: Ethyl (1S, 2S)-2-(2-oxoazepan-1-yl)cyclopropane-1-carboxylate. The reaction was 
performed on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer 
expressing P411-VACtrans at 6.1 μM, with 5 mM N-vinylcaprolactam (added as 1 mL of a 125 mM 
solution in DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product 
was purified by silica gel chromatography (0 to 100% EtOAc/hexanes) and isolated as a clear oil 
(17.5 mg, 62% yield, 510 TTN, 7:93 dr, 86% ee). 1H NMR (400 MHz, CDCl3) δ 4.14 (qd, J = 7.1, 
0.8 Hz, 2H), 3.36 (dd, J = 6.2, 3.9 Hz, 2H), 3.15 (ddd, J = 7.7, 5.3, 3.1 Hz, 1H), 2.52 – 2.45 (m, 
2H), 1.78 (ddd, J = 9.1, 5.9, 3.1 Hz, 1H), 1.72 – 1.58 (m, 6H), 1.48 (dt, J = 7.7, 5.7 Hz, 1H), 1.28 
– 1.19 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 177.51, 172.57, 60.94, 60.81, 50.31, 39.38, 37.76, 
29.96, 29.16, 23.48, 23.04, 16.76, 14.35. HRMS (ESI) exact mass calculated for C12H19NO3+ 
requires m/z 226.1443, found 226.1425. 
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Determination of N-vinylcaprolactam cyclopropanation enantioselectivity. Reaction mixtures 
were extracted with cyclohexane, or purified compounds were dissolved in 20% isopropanol in 
hexanes, and samples were analyzed by chiral HPLC using a Chiralpak IC column (cis product: 
40% isopropanol, isocratic, 1 mL/min flow rate; trans product: 50% isopropanol, isocratic, 1.2 
mL/min flow rate).  
Racemic cis isomer, chemically prepared: 
 
Enzymatic reaction with P411-VACcis V87T (88% ee cis): 
 
Racemic trans isomer, chemically prepared: 
 
Enzymatic reaction, with P411-VACtrans (86% ee trans): 
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5a: Ethyl (1S, 2R)-2-(2-oxopyrrolidin-1-yl)cyclopropane-1-carboxylate. The reaction was 
performed on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer 
expressing P411-VACcis V87T at 1.5 μM, with 5 mM N-vinylpyrrolidone (added as 1 mL of a 125 
mM solution in DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The 
product was purified by silica gel chromatography (0 to 100% EtOAc/hexanes) and isolated as a 
clear oil (14.5 mg, 59% yield, 1960 TTN, 97:3 dr, 74% ee). 1H NMR (400 MHz, CDCl3) δ 4.10 
(q, J = 7.2 Hz, 2H), 3.61 – 3.50 (m, 1H), 3.33 (ddd, J = 9.1, 7.5, 5.8 Hz, 1H), 3.00 (qt, J = 7.2, 0.9 
Hz, 1H), 2.38 – 2.32 (m, 2H), 2.08 – 1.98 (m, 3H), 1.51 (q, J = 6.1 Hz, 1H), 1.31 – 1.23 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 177.08, 170.96, 60.96, 48.54, 32.82, 31.60, 20.78, 18.69, 14.29, 
12.57. HRMS (ESI) exact mass calculated for C10H15NO3
+ requires m/z 198.1130, found 198.1113. 
 
 
 
 
5b: Ethyl (1S, 2S)-2-(2-oxopyrrolidin-1-yl)cyclopropane-1-carboxylate. The reaction was 
performed on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer 
expressing P411-VACtrans at 6.1 μM, with 5 mM N-vinylpyrrolidone (added as 1 mL of a 125 mM 
solution in DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product 
was purified by silica gel chromatography (0 to 100% EtOAc/hexanes) and isolated as a clear oil 
(14 mg, 57% yield, 470 TTN, 5:95 dr, 92% ee). 1H NMR (400 MHz, CDCl3) δ 4.15 (qd, J = 7.2, 
1.5 Hz, 2H), 3.36 – 3.29 (m, 2H), 3.18 (dddt, J = 8.0, 5.3, 3.1, 0.8 Hz, 1H), 2.40 (t, J = 8.1 Hz, 
2H), 2.05 – 1.97 (m, 2H), 1.86 (ddd, J = 9.1, 5.9, 3.1 Hz, 1H), 1.48 (dt, J = 8.0, 5.8 Hz, 1H), 1.42 
(dt, J = 9.2, 5.5 Hz, 1H), 1.28 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.14, 172.38, 
61.03, 47.38, 34.15, 31.77, 19.86, 18.12, 14.29, 14.20. HRMS (ESI) exact mass calculated for 
C10H15NO3
+ requires m/z 198.1130, found 198.1140. 
 
Determination of N-vinylpyrrolidone cyclopropanation enantioselectivity. Reaction mixtures 
were extracted with cyclohexane, or purified compounds were dissolved in 20% isopropanol in 
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hexanes, and samples were analyzed by chiral HPLC. Cis product: Chiralpak IA column, 20% 
isopropanol, isocratic, 1 mL/min flow rate; trans product: Chiralpak OJ-H column, 5% 
isopropanol, isocratic, 1 mL/min flow rate.  
 
Racemic cis isomer, chemically prepared: 
 
Enzymatic reaction with P411-VACcis V87T (74% ee cis): 
 
Racemic trans isomer, chemically prepared: 
 
Enzymatic reaction, with P411-VACtrans (92% ee trans): 
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6a: Ethyl (1S, 2R)-2-(N-methylacetamido)cyclopropane-1-carboxylate. The reaction was 
performed on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer 
expressing P411-VACcis E267N at 1.1 μM, with 5 mM N-methyl-N-vinylacetamide (added as 
1 mL of a 125 mM solution in DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in 
EtOH). The product was purified by silica gel chromatography (0 to 100% EtOAc/hexanes) and 
isolated as a clear oil (8.5 mg, 37% yield, 1700 TTN, 94:6 dr, 97% ee). 1H NMR (400 MHz, 
CDCl3) Mixture of rotamers: δ 4.19 – 4.03 (m, 2H), 3.20 – 3.06 (m, 1H), 3.04 – 2.88 (m, 3H), 2.19 
– 1.98 (m, 4H), 1.74 – 1.67 (m, 1H), 1.46 – 1.34 (m, 1H), 1.29 – 1.19 (m, 3H). 13C NMR (101 
MHz, CDCl3) δ 172.76, 172.62, 171.02, 169.61, 61.03, 60.59, 39.40, 37.93, 36.88, 33.92, 23.33, 
22.26, 22.09, 21.85, 14.49, 14.12, 14.05, 13.52. HRMS (ESI) exact mass calculated for C9H15NO3
+ 
requires m/z 186.1130, found 186.1120. 
 
 
 
 
6b: Ethyl (1S, 2S)-2-(N-methylacetamido)cyclopropane-1-carboxylate. The reaction was 
performed on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer 
expressing P411-VACtrans at 6.9 μM, with 5 mM N-methyl-N-vinylacetamide (added as 1 mL of a 
125 mM solution in DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). 
The product was purified by silica gel chromatography (0 to 100% EtOAc/hexanes) and isolated 
as a clear oil (15 mg, 65% yield, 470 TTN, 4:96 dr, 95% ee). 1H NMR (400 MHz, CDCl3) δ 4.17 
(q, J = 7.1 Hz, 2H), 3.15 (ddd, J = 7.8, 5.1, 3.0 Hz, 1H), 2.89 (s, 3H), 2.16 (s, 3H), 1.91 (ddd, J = 
9.2, 5.9, 3.0 Hz, 1H), 1.54 (dt, J = 7.7, 5.7 Hz, 1H), 1.33 (dt, J = 9.4, 5.3 Hz, 1H), 1.27 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.18, 171.73, 61.29, 40.20, 33.77, 24.22, 22.56, 17.66, 
14.36. HRMS (ESI) exact mass calculated for C9H15NO3
+ requires m/z 186.1130, found 186.1100. 
 
Determination of N-methyl-N-vinylacetamide cyclopropanation enantioselectivity. Reaction 
mixtures were extracted with cyclohexane, or purified compounds were dissolved in 20% 
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isopropanol in hexanes, and samples were analyzed by chiral HPLC using a Chiralpak IC column, 
40% isopropanol, isocratic, 1 mL/min flow rate.  
Racemic cis isomer, chemically prepared: 
 
Enzymatic reaction with P411-VACcis E267N (97% ee cis): 
 
Racemic trans isomer, chemically prepared: 
 
Enzymatic reaction, with P411-VACtrans (95% ee trans): 
  
32 
 
 
 
 
7a: Ethyl cis-2-phenoxycyclopropane-1-carboxylate. The reaction was performed on 0.125 
mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer expressing P411-VACcis 
V87T at 1.5 μM, with 5 mM phenyl vinyl ether (added as 1 mL of a 125 mM solution in DMSO) 
and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product was purified by 
silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a clear oil (17 mg, 66% yield, 
2200 TTN, 72:28 dr, 87% ee). 1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H), 7.03 (dd, J = 
8.8, 1.1 Hz, 2H), 6.99 – 6.94 (m, 1H), 4.03 – 3.95 (m, 3H), 2.02 (dt, J = 8.8, 6.8 Hz, 1H), 1.77 
(ddd, J = 6.9, 6.3, 4.6 Hz, 1H), 1.32 (dt, J = 8.8, 6.5 Hz, 1H), 1.04 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.21, 158.24, 129.49, 121.66, 115.09, 60.83, 55.61, 21.49, 14.15, 12.98. 
HRMS (EI+) exact mass calculated for C12H14O3
+ requires m/z 206.0943, found 206.0925. 
 
 
 
 
7b: Ethyl trans-2-phenoxycyclopropane-1-carboxylate. The reaction was performed on 0.125 
mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer expressing P411-VACcis 
V87I at 1.3 μM, with 5 mM phenyl vinyl ether (added as 1 mL of a 125 mM solution in DMSO) 
and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product was purified by 
silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a clear oil (19 mg, 74% yield, 
2800 TTN, 2:98 dr, 94% ee). 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.27 (m, 2H), 7.03 – 6.95 (m, 
3H), 4.20 (qd, J = 7.1, 2.4 Hz, 2H), 4.07 (ddd, J = 6.5, 4.1, 2.1 Hz, 1H), 1.95 (ddd, J = 9.8, 6.2, 
2.1 Hz, 1H), 1.51 (dt, J = 6.7, 6.0 Hz, 1H), 1.42 (ddd, J = 9.9, 5.8, 4.1 Hz, 1H), 1.30 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 172.25, 158.06, 129.67, 121.79, 114.99, 61.02, 57.28, 21.77, 
15.78, 14.43. HRMS (EI+) exact mass calculated for C12H14O3
+ requires m/z 206.0943, found 
206.0917. 
 
Determination of phenyl vinyl ether cyclopropanation enantioselectivity. Reaction mixtures 
were extracted with cyclohexane, or purified compounds were dissolved in 20% isopropanol in 
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hexanes, and samples were analyzed by chiral HPLC using a Chiralpak IC column (trans product: 
1% isopropanol, isocratic, 1 mL/min flow rate; cis product: 7.5% isopropanol, isocratic, 1 mL/min 
flow rate). 
Racemic cis isomer, chemically prepared: 
 
Enzymatic reaction, with P411-VACcis V87T (87% ee cis): 
 
Racemic trans isomer, chemically prepared: 
 
Enzymatic reaction with P411-VACcis V87I (94% ee trans):  
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8a: Ethyl cis-2-(phenylthio)cyclopropane-1-carboxylate. The reaction was performed on 0.125 
mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer expressing P411-VACcis 
A328N at 1.6 μM, with 5 mM phenyl vinyl sulfide (added as 1 mL of a 125 mM solution in DMSO) 
and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product was purified by 
silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a clear oil (12 mg, 43% yield, 
1400 TTN, 84:16 dr, 90% ee). 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.32 (m, 2H), 7.30 – 7.22 (m, 
2H), 7.17 – 7.10 (m, 1H), 4.04 (q, J = 7.1 Hz, 2H), 2.69 (td, J = 7.9, 6.9 Hz, 1H), 2.23 (td, J = 7.7, 
6.7 Hz, 1H), 1.49 – 1.43 (m, 2H), 1.09 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.81, 
137.27, 128.87, 127.60, 125.65, 60.98, 22.22, 22.18, 14.24, 13.33. HRMS (EI+) exact mass 
calculated for C12H14O2S requires m/z 222.0715, found 222.0717. 
 
 
 
 
8b: Ethyl trans-2-(phenylthio)cyclopropane-1-carboxylate. The reaction was performed on 
0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer expressing P411-
VACcis V87F at 1.7 μM, with 5 mM phenyl vinyl sulfide (added as 1 mL of a 125 mM solution in 
DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product was 
purified by silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a clear oil (16 
mg, 58% yield, 1700 TTN, 13:87 dr, 84% ee). 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.27 (m, 4H), 
7.21 – 7.15 (m, 1H), 4.18 (qd, J = 7.1, 6.1 Hz, 2H), 2.76 (ddd, J = 8.2, 5.6, 3.6 Hz, 1H), 1.91 (ddd, 
J = 8.8, 5.4, 3.6 Hz, 1H), 1.66 (ddd, J = 8.2, 5.4, 4.8 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H), 1.25 – 1.20 
(m, 1H). 13C NMR (101 MHz, CDCl3) δ 172.47, 136.96, 129.08, 127.35, 125.87, 61.14, 24.33, 
22.44, 17.42, 14.40. HRMS (EI+) exact mass calculated for C12H14O2S requires m/z 222.0715, 
found 222.0706. 
 
Determination of phenyl vinyl sulfide cyclopropanation enantioselectivity. Reaction mixtures 
were extracted with cyclohexane, or purified compounds were dissolved in 20% isopropanol in 
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hexanes, and samples were analyzed by chiral HPLC using a Chiralpak IA column, 1% 
isopropanol, isocratic, 1 mL/min flow rate. 
 
Racemic cis isomer, chemically prepared: 
 
Enzymatic reaction, with P411-VACcis A328N (90% ee cis): 
 
Racemic trans isomer, chemically prepared: 
 
Enzymatic reaction with P411-VACcis V87F (84% ee trans): 
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9a: Ethyl cis-2-(9H-carbazol-9-yl)cyclopropane-1-carboxylate. The reaction was performed on 
0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer expressing P411-
VACcis A328S at 1.4 μM, with 5 mM N-vinylcarbazole (added as 1 mL of a 125 mM solution in 
DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product was 
purified by silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a white solid 
(13 mg, 37% yield, 1300 TTN, 64:36 dr, 62% ee). 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 7.7 
Hz, 2H), 7.66 – 7.48 (m, 2H), 7.43 (t, J = 7.6 Hz, 2H), 7.22 (ddd, J = 8.0, 7.2, 1.0 Hz, 2H), 3.75 
(td, J = 7.2, 5.7 Hz, 1H), 3.61 (qd, J = 7.1, 2.1 Hz, 2H), 2.40 (ddd, J = 8.6, 7.0, 6.4 Hz, 1H), 2.20 
(dt, J = 6.4, 5.7 Hz, 1H), 1.84 (ddd, J = 8.6, 7.4, 5.5 Hz, 1H), 0.69 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.69, 141.41, 125.75, 123.26, 120.40, 119.57, 109.88, 60.85, 31.97, 21.47, 
14.06, 13.57. HRMS (FAB+) exact mass calculated for C18H17NO2
+ requires m/z 280.1338, found 
280.1310. 
 
 
9b: Ethyl trans-2-(9H-carbazol-9-yl)cyclopropane-1-carboxylate. The reaction was performed 
on 0.125 mmol scale with whole-cell catalysts at OD600=50 in 23 mL M9-N buffer expressing 
P411-VACtrans at 7.6 μM, with 5 mM N-vinylcarbazole (added as 1 mL of a 125 mM solution in 
DMSO) and 10 mM EDA (added as 1 mL of a 250 mM solution in EtOH). The product was 
purified by silica gel chromatography (0 to 30% EtOAc/hexanes) and isolated as a clear oil (19 mg, 
54% yield, 360 TTN, 6:94 dr, 94% ee). 1H NMR (400 MHz, CDCl3) δ 8.04 (ddd, J = 7.8, 1.1, 0.7 
Hz, 2H), 7.54 (dt, J = 8.2, 0.8 Hz, 2H), 7.45 (ddd, J = 8.2, 7.1, 1.2 Hz, 2H), 7.24 (ddd, J = 8.0, 7.1, 
1.0 Hz, 2H), 4.32 (qd, J = 7.1, 2.0 Hz, 2H), 3.72 (ddd, J = 7.5, 4.8, 2.8 Hz, 1H), 2.27 (ddd, J = 9.3, 
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5.9, 2.8 Hz, 1H), 1.95 (ddd, J = 7.3, 5.9, 5.1 Hz, 1H), 1.69 (dt, J = 9.2, 5.0 Hz, 1H), 1.38 (t, J = 7.2 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.07, 140.92, 126.05, 123.28, 120.47, 119.83, 109.89, 
61.44, 32.73, 22.27, 16.17, 14.53. HRMS (FAB+) exact mass calculated for C18H17NO2
+ requires 
m/z 280.1338, found 280.1322. 
 
Determination of N-vinylcarbazole cyclopropanation enantioselectivity. Reaction mixtures 
were extracted with cyclohexane, or purified compounds were dissolved in 20% isopropanol in 
hexanes, and samples were analyzed by chiral HPLC using a Chiralpak IC column (cis product: 
5% isopropanol, isocratic, 1 mL/min flow rate; trans product: 1% isopropanol, isocratic, 1 mL/min 
flow rate).  
 
Racemic cis isomer, chemically prepared: 
 
Enzymatic reaction with P411-VACcis A328S (62% ee cis): 
 
38 
 
Racemic trans isomer, chemically prepared: 
 
Enzymatic reaction, with P411-VACtrans (94% ee trans): 
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V. NMR spectra 
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VI. Nucleotide and amino acid sequences of evolved P411 variants 
 
Nucleotide sequence of cytochrome P411-VACcis 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAA
ACACAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATT
CGAGGCGCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGAT
GAATCACGCTTTGATAAAAACTTAAGTCAAGCGTATAAATTTGCACGTGATTTTGCAGGAGACG
GGTTAGTGACAAGCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAG
CTTTAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTT
CAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAA
CGCTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCC
TCATCCATTTATTATAAGTATGGTCCGTGCAATTGATGAAGTAATGAACAAGCTGCAGCGAGCA
AATCCAGACGACCCAGCTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGA
ACGACCTAGTAGATAAAATTATTGCAGATCGCAAAGCAAGGGGTGAACAAAGCGATGATTTATT
AACGCAGATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTTGATGACGGGAACATTCGC
TATCAAATTATTACATTCTTAATTGCGGGACACGAAGCAACAAGTGGTCTTTTATCATTTGCGC
TGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCACGAGTTCT
AGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAAC
GAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGC
TTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGATTCCTCAGCTTCACCG
TGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGT
GCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTCTATCGGTCAGCAGT
TCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAAGATCA
TACAAACTACGAGCTCGATATTAAAGAAACTTTTCAGTTAAAACCTAAAGGCTTTGTGGTAAAA
GCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAAA
AAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATAT
GGGTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCG
CAGGTCGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAA
CGGCGTCTTATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGC
GTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGGGCT
ACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACA
TCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGA
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ACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAA
TCTACTCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTG
CGTTTTCAACGAACGTCGTAGCAAGCAAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCG
ACATCTTGAAATTGAACTTCCAAAAGAAGCTTCTTATCAAGAAGGAGATCATTTAGGTGTTATT
CCTCGCAACTATGAAGGAATAGTAAACCGTGTAACAGCAAGGTTCGGCCTAGATGCATCACAGC
AAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCTCATTTGCCACTCGCTAAAACAGTATCCGT
AGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTGTTACGCGCACGCAGCTTCGCGCAATG
GCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGAAGCCTTGCTTGAAAAGCAAGCCT
ACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTGCTTGAAAAATACCCGGCGTG
TGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCCCGCGCTATTACTCGATT
TCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGTTGTCTCAGGAGAAG
CGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAGCTGCAAGAAGG
AGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAGACCCTGAA
ACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCAGGCGC
GCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGTTC
ACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACG
CTTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAAC
AAGACGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGG
AAGCCAAATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTG
AGTGAAGCAGACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACG
TGTGGGCTGGGCTCGAGCACCACCACCACCACCACTGA 
 
 
Amino acid sequence of cytochrome P411-VACcis 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACD
ESRFDKNLSQAYKFARDFAGDGLVTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLV
QKWERLNADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRAIDEVMNKLQRA
NPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIR
YQIITFLIAGHEATSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLN
EALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPS
AIPQHAFKPFGNGQRASIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETFQLKPKGFVVK
AKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAP
55 
 
QVATLDSHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWA
TTYQKVPAFIDETLAAKGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNK
STLSLQFVDSAADMPLAKMHGAFSTNVVASKELQQPGSARSTRHLEIELPKEASYQEGDHLGVI
PRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLPLAKTVSVEELLQYVELQDPVTRTQLRAM
AAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSIRPRYYSI
SSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSEFTLPKDPE
TPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIIT
LHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYADVHQV
SEADARLWLQQLEEKGRYAKDVWAGLEHHHHHH 
 
 
Nucleotide sequence of cytochrome P411-VACtrans 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAA
ACACAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATT
CGAGGCGCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGAT
GAATCACGCTTTGATAAAAACTTAAGTCAAGCGCTGAAATTTGCACGTGATTTTGCAGGAGACG
GGTTACTGACAAGCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAG
CTTTAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTT
CAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAA
CGCTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCC
TCATCCATTTATTATAAGTATGGTCCGTGCACGTGATGAAGTAATGAACAAGCTGCAGCGAGCA
AATCCAGACGACCCAGCTTATGATGAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGA
ACGACCTAGTAGATAAAATTATTGCAGATCGCAAAGCAAGGGGTGAACAAAGCGATGATTTATT
AACGCAGATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTTGATGACGGGAACATTCGC
TATCAAATTATTACATTCTTAGGAGCGGGACACGAAGCAACAAGTGGTCTTTTATCATTTGCGC
TGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTAGCAGAAGAAGCAGCACGAGTTCT
AGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAAC
GAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGC
TTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGATTCCTCAGCTTCACCG
TGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGT
GCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTCTATCGGTCAGCAGT
TCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAAGATCA
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TACAAACTACGAGCTCGATATTAAAGAAACTTTTACCTTAAAACCTAAAGGCTTTGTGGTAAAA
GCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAAA
AAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATAT
GGGTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCG
CAGGTCGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAA
CGGCGTCTTATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGC
GTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGGGCT
ACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACA
TCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGA
ACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAA
TCTACTCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTG
CGTTTTCAACGAACGTCGTAGCAAGCAAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCG
ACATCTTGAAATTGAACTTCCAAAAGAAGCTTCTTATCAAGAAGGAGATCATTTAGGTGTTATT
CCTCGCAACTATGAAGGAATAGTAAACCGTGTAACAGCAAGGTTCGGCCTAGATGCATCACAGC
AAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCTCATTTGCCACTCGCTAAAACAGTATCCGT
AGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTGTTACGCGCACGCAGCTTCGCGCAATG
GCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGAAGCCTTGCTTGAAAAGCAAGCCT
ACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTGCTTGAAAAATACCCGGCGTG
TGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCCCGCGCTATTACTCGATT
TCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGTTGTCTCAGGAGAAG
CGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAGCTGCAAGAAGG
AGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAGACCCTGAA
ACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCAGGCGC
GCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGTTC
ACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACG
CTTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAAC
AAGACGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGG
AAGCCAAATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTG
AGTGAAGCAGACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACG
TGTGGGCTGGGCTCGAGCACCACCACCACCACCACTGA 
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Amino acid sequence of cytochrome P411-VACtrans 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACD
ESRFDKNLSQALKFARDFAGDGLLTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLV
QKWERLNADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRARDEVMNKLQRA
NPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIR
YQIITFLGAGHEATSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLN
EALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPS
AIPQHAFKPFGNGQRASIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETFTLKPKGFVVK
AKSKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAP
QVATLDSHAGNLPREGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWA
TTYQKVPAFIDETLAAKGAENIADRGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNK
STLSLQFVDSAADMPLAKMHGAFSTNVVASKELQQPGSARSTRHLEIELPKEASYQEGDHLGVI
PRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLPLAKTVSVEELLQYVELQDPVTRTQLRAM
AAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSIRPRYYSI
SSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSEFTLPKDPE
TPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIIT
LHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYADVHQV
SEADARLWLQQLEEKGRYAKDVWAGLEHHHHHH
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